CBT-007

CBT-007 is developed for improving success rate of glaucoma filtration surgery (GFS). GFS is an effective way to lower high intraocular pressure (IOP) in patients with glaucoma by increasing the outflow of fluid from the eye. However, excess scarring and fibrosis after surgery can lead to blockage of the drainage and cause failure of GFS over time. The usage of anti-fibrotic antimetabolite drugs such as mitomycin C (“MMC”) can improve the success rate of GFS, but these cytotoxic agents can also cause various adverse complications.

CBT-007 is an eye drop being developed for improving the success rate of GFS. It is intended to be used as adjunct therapy with MMC to potentially lower the amount of MMC needed. CBT-007 targets key pathogenic pathways that contribute to GFS failure, including the vascular endothelial growth factor (VEGF) and the fibroblast growth factor (FGF) signaling pathways. Attenuation of these pathways is expected to delay or prevent the post-surgical complication of fibrosis that can lead to bleb blockage and contribute to surgical failure.